{
    "clinical_study": {
        "@rank": "93987", 
        "arm_group": {
            "arm_group_label": "tissue", 
            "description": "This is a protocol to obtain and/or analyze tumor and germline DNA specimens of patients with MPM, choroidal nevus, and UM."
        }, 
        "biospec_descr": {
            "textblock": "tissue specimens blood or saliva sample"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The goal of this protocol is to determine the prevalence of somatic and germline mutations\n      in BAP1 (BRCA associated protein-1) among patients with mesothelioma , choroidal nevus,\n      primary uveal melanoma (UM), or metastatic UM seen at our institution."
        }, 
        "brief_title": "Clinical and Histopathologic Characteristics of BAP1 Mutations", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Malignant Pleural Mesothelioma (MPM)", 
            "Choroidal Nevus", 
            "Primary Uveal Melanoma (UM)", 
            "Metastatic Uveal Melanoma (UM)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Melanoma", 
                "Mesothelioma", 
                "Uveal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        All consents:\n\n          -  > or = to 18 years of age\n\n          -  Ability to provide informed consent\n\n        Consent 1:\n\n        Mesothelioma\n\n          -  Histologically proven diagnosis of Mesothelioma OR Choroidal nevus\n\n          -  Diagnosis of choroidal nevus by direct examination and/or ultrasound/optical\n             coherence tomography and possibly fluorescein angiography OR Primary uveal melanoma\n\n          -  Diagnosis of uveal melanoma by direct examination and/or ultrasound/optical coherence\n             tomography and possibly fluorescein angiography\n\n        Consent 2:\n\n        Mesothelioma\n\n          -  Histologically proven diagnosis of Mesothelioma AND\n\n          -  BAP1 mutation or loss of expression identified in tumor sample\n\n        OR one of the following:\n\n          -  Age<50 at diagnosis\n\n          -  No history of asbestos exposure\n\n          -  Personal history of choroidal nevus, uveal melanoma, or melanoma\n\n          -  Family history of choroidal nevus, uveal melanoma, or mesothelioma\n\n          -  History of malignancy in more than two first-degree relatives OR Choroidal nevus\n\n          -  Diagnosis of choroidal nevus by direct examination and/or ultrasound/optical\n             coherence tomography and possibly fluorescein angiography AND one of the following:\n\n          -  More than one clinical risk factor, which may include: orange pigment, thickness > 1\n             < 2.5mm\n\n          -  Personal history of uveal melanoma, skin melanoma, or mesothelioma\n\n          -  Family history of choroidal nevus, uveal melanoma, or mesothelioma OR Primary uveal\n             melanoma\n\n          -  Diagnosis of uveal melanoma by direct examination and/or ultrasound/optical coherence\n             tomography and possibly fluorescein angiography\n\n        AND one of the following:\n\n          -  Personal history of uveal melanoma, skin melanoma, or mesothelioma\n\n          -  Family history of choroidal nevus, uveal melanoma, or mesothelioma\n\n          -  History of malignancy in more than two first-degree relatives OR Metastatic uveal\n             melanoma\n\n          -  Histologically proven diagnosis of metastatic uveal melanoma AND\n\n          -  BAP1 mutation or loss of expression identified in tumor sample\n\n        OR one of the following:\n\n          -  Personal history of uveal melanoma, skin melanoma, or mesothelioma\n\n          -  Family history of choroidal nevus, uveal melanoma, or mesothelioma\n\n          -  History of malignancy in more than two first-degree relatives\n\n        Consent 3:\n\n          -  Relative of patient with germline BAP1 mutation identified through identified testing\n\n        Exclusion Criteria:\n\n          -  none"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "MSKCC's clinics"
            }
        }, 
        "enrollment": {
            "#text": "460", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01773655", 
            "org_study_id": "12-235"
        }, 
        "intervention": {
            "arm_group_label": "tissue", 
            "description": "All consenting patients (Consent 1) will participate in an anonymized assessment of the prevalence of germline BAP1 mutations. Available tumor specimens from patients with MPM and metastatic uveal melanoma will be tested for BAP1 mutation. Patients whose tumors harbor BAP1 mutations and/or meet the criteria for germline mutation specified in 2.2.2 will be approached for identified germline BAP1 testing after appropriate pre-test counseling (Consent 2).\nPatients who, through identified testing, are found to have germline BAP1 mutations will be asked to invite their relatives to participate in germline testing (Consent 3). First-degree relatives and any relatives with a malignancy will be prioritized. Expanding testing to family members of patients with BAP1 germline mutations is essential to delineate the penetrance and describe the various manifestations of this new cancer predisposition syndrome.", 
            "intervention_name": "tumor specimens", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "somatic", 
            "germline", 
            "mutations", 
            "BAP1 (BRCA associated protein-1)", 
            "12-235"
        ], 
        "lastchanged_date": "January 20, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": {
            "contact": {
                "last_name": "Marjorie Zauderer, MD", 
                "phone": "646-888-4656"
            }, 
            "contact_backup": {
                "last_name": "David Abramson, MD", 
                "phone": "212-639-7232"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "Memorial Sloan Kettering Cancer Center"
            }, 
            "investigator": {
                "last_name": "Marjorie Zauderer, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Clinical and Histopathologic Characteristics of BAP1 Mutations", 
        "overall_contact": {
            "last_name": "Marjorie Zauderer, MD", 
            "phone": "646-888-4656"
        }, 
        "overall_contact_backup": {
            "last_name": "David Abramson, M.D.", 
            "phone": "212-639-7232"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Marjorie Zauderer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Prevalence will be estimated as the proportion of all specimens who tested positive for mutation, and reported along with the corresponding exact 95% confidence intervals.", 
            "measure": "determine the prevalence of germline BAP1 mutations", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01773655"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The frequency of somatic mutations will be tabulated by factors of interest such as:\npersonal and familial risk factors: age, smoking, and asbestos mesothelioma, personal and family history of cancer or of related diseases (mesothelioma and metastatic uveal melanoma)\ndisease characteristics: histology, stage, location, site of metastasis (if present) (for mesothelioma and metastatic uveal melanoma); COMS criteria, GEP class, number of clinical risk factors (for metastatic uveal melanoma)", 
            "measure": "prevalence of somatic BAP1 mutations in disease mesothelioma and metastatic uveal melanoma.", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}